Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Other Non Operating Income: 2014-2025

Historic Other Non Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $7.8 million.

  • Viking Therapeutics' Other Non Operating Income fell 33.08% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 7.56%. This contributed to the annual value of $41.0 million for FY2024, which is 174.30% up from last year.
  • As of Q3 2025, Viking Therapeutics' Other Non Operating Income stood at $7.8 million, which was down 13.75% from $9.0 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Other Non Operating Income registered a high of $11.8 million during Q2 2024, and its lowest value of $142,000 during Q1 2022.
  • In the last 3 years, Viking Therapeutics' Other Non Operating Income had a median value of $7.8 million in 2025 and averaged $7.5 million.
  • In the last 5 years, Viking Therapeutics' Other Non Operating Income crashed by 84.53% in 2021 and then spiked by 2,168.84% in 2023.
  • Viking Therapeutics' Other Non Operating Income (Quarterly) stood at $154,000 in 2021, then skyrocketed by 370.13% to $724,000 in 2022, then soared by 546.41% to $4.7 million in 2023, then surged by 131.22% to $10.8 million in 2024, then plummeted by 33.08% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $9.0 million for Q2 2025, and $9.8 million during Q1 2025.